Veterinary Biologics Market
Report ID: SQMIG35A3094
Report ID: SQMIG35A3094
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35A3094 |
Region:
Global |
Published Date: August, 2025
Pages:
170
|Tables:
117
|Figures:
72
Global Veterinary Biologics Market size was valued at USD 27.58 Billion in 2024 and is poised to grow from USD 28.77 Billion in 2025 to USD 40.32 Billion by 2033, growing at a CAGR of 4.31% in the forecast period (2026–2033).
The increased focus on animal health, growing awareness by companion animal owners, and increasing incidence of zoonotic diseases are attracting significant investment in the veterinary biologics sector. Other contributors to overall market growth include an increase in pet ownership, increased focus on companion animal health, and growth of livestock production systems. Additionally, the veterinary biologics market growth is being propelled by increased development of recombinant vaccines, improved biotechnological platforms, and robust government support in preemptive government programs aimed at animal disease control. There are numerous opportunities for growth across cattle, chickens, companion animals, aquaculture, and others. This is expected to drive the veterinary biologics industry forward in the coming years.
The advancement of next-generation biologics such as DNA vaccines, monoclonal antibodies, and vector-based vaccines; advances in cold chain logistics systems; and increased efforts by manufacturers to reach remote and underserved areas are designed to advance animal welfare and increase vaccine efficacy through important partnerships and collaboration, as well as R&D investments.
Why Is AI Integration Important for the Future of Veterinary Biologics?
AI is impacting veterinary biologics through breakthroughs in data-driven diagnostics, predictive modelling, and focused vaccine development. AI platforms increasingly help researchers optimize formulations, manage field trials in real-time, and improve decision-making throughout regulatory processes.
Market snapshot - 2026-2033
Global Market Size
USD 26.44 billion
Largest Segment
Cell Culture
Fastest Growth
Recombinant Technologies
Growth Rate
4.31% CAGR
To get more insights on this market click here to Request a Free Sample Report
The veterinary biologics market is segmented into type, species, target disease, source, and region. By type, the market is classified into vaccines, antibiotics, Antiparasitic, and growth promoters. Depending on the species, it is bifurcated into livestock and companion animals. According to target disease, the market is divided into bacterial infections, viral infections, parasitic infections, and metabolic disorders. As per the supported source, it is categorised into cell culture, inactivated pathogens, and recombinant technologies. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Why are Cell Culture Taking Over Veterinary Biologics Market?
As per veterinary biologics market analysis, Cell culture-based biologics dominated the market due to their scale and reproducible production quality. These sources require no whole-pathogen processing and facilitate a more rapid and cleaner antigen extraction. This is a common source for viral vaccine development, enhanced by speed, reproducibility, and potential to respond to emerging diseases using higher throughput. Biosecurity perceptions and biopharma investment are also positively correlated to the rise of cell culture-based manufacturing as a foundational pillar in veterinary vaccine pipelines.
Recombinant technologies will exhibit the fastest segment growth during the period between 2025-2032. Recombinant biologics provide better antigen specificity, fewer adverse side effects and can be produced faster, so vaccines can be rapidly developed as strains emerge. As there is an increase in R&D expenditures from biotechnology companies developing animal health products, recombinant technologies will be further applied to the development of new immunotherapeutics, especially companion animals and poultry.
Why Are Livestock Applications Leading Veterinary Biologics Market?
Based on Veterinary Biologics market forecast, the dominant species within the market is livestock animals, largely based on features such as their importance in global food supply chains and the financial impact of whether cattle, poultry, or swine are housed and bred. Many governments in developing countries are beginning to mandate vaccination or programs for disease control to preserve public health and sustain production output. Cattle are expected to have the most sustained demand for livestock biologics, specifically livestock biologics for bovine respiratory diseases, avian influenza, and foot-and-mouth disease. Large producers are dealing with the morbidity and mortality of these animals, and biologics are expected to provide viable solutions.
Companion Animals is anticipated to have the largest veterinary biologics market share owing to its involvement as pet adoption is on the rise, pet owners, and therefore consumers, are spending more funds on pet healthcare, and there is an overall increase in human emotional and ethical practices towards animals. Urban pet owners use veterinarians to provide not only personalized care and wellness biologics but also advanced therapeutics, including DNA-based vaccines and monoclonal antibodies. Urban pet owners are driving new trends linking companion animal care into existing welfare and educational programs, as well as leading to improvement in retail markets for biologics including veterinarians, wholesalers, e-commerce platforms, and convenient digital health for pets, all of which is promoting greater access and increased uptake in urban and semi-urban homes.
To get detailed segments analysis, Request a Free Sample Report
What Factors Are Driving Growth of the Veterinary Biologics Market in Asia-Pacific?
As per the veterinary biologics market regional analysis, Asia-Pacific dominated the global market. Asia-Pacific is on track to be the fastest-growing veterinary biologics market, with India and China leading the charge. India has a biological manufacturing capacity that has exploded over the last 5 years, often spearheaded by government efforts to bolster veterinary infrastructure and boost livestock productivity. Vaccination campaigns for foot-and-mouth disease and brucellosis are widespread, and there is an increasing trend for local players to innovate lower-cost biologic formulations. In China, growing concerns around zoonotic outbreaks and food security are leading to a greater need for preventive biologics for both livestock and aquaculture; urbanization and the demand for companion animal biologics are increasing in both countries.
Veterinary Biologics Market in India
India's veterinary biologics sector is rapidly expanding, as reflected by the country's immense livestock ownership and a government interest in disease eradication programs. The National Animal Disease Control programme (NADCP) facilitates the mass vaccination against foot-and-mouth disease and brucellosis, creating exceptional demand for vaccines. Increased production and local biologics companies, often with government support via a Make in India program, can help meet local and international animal health needs. There is also an emerging market for companion animal biologics, with more pet adoption and veterinary services available in urban India.
Veterinary Biologics Market in China
China market growth is driven by heightened awareness about food security and zoonotic disease control, particularly considering COVID-19. The country has enormous pig and poultry farming environments, and both within those environments and next to them, there is an apparent shift toward promoting and using biologics to enhance disease prevention and reduce reliance on antibiotics. The government also promotes preventive care and is spending on next-gen biotechnology platforms to keep more of the biologics production within China. The rise in urban pet culture has contributed to the increases in both pet-specific vaccines and therapeutic biologics. Both categories are fueled by strong e-commerce distribution networks.
How Is Technology Shaping the Future of Veterinary Biologics in North America?
North America remains strong in the veterinary biologics market share, led by the United States and Canada, which have governmental support for animal disease control, a high rate of pet ownership, and a large veterinary healthcare infrastructure. The presence of large companies like Zoetis and Elanco in the U.S. supports the innovation of products like vaccines and recombinant biologics, as well as biomanufacturing facilities and funding support for R&D programs for the advancement of products. Agricultural regulatory bodies (e.g. the USDA) are also a big part of this regulation and assist in setting safety standards while facilitating the approval process for biologics.
Veterinary Biologics Market in the United States
The United States offer the most attractive market for veterinary biologics and continue to remain strong from 2025 to 2035, supported by a robust infrastructure of advanced veterinary healthcare, high levels of investment in animal health. The regulatory regime is a combination of the U.S. Department of Agriculture (USDA) and the FDA to provide clarity and a strong regulatory assurance of the safety (and efficacy) of products, which is attractive for adoption and growth.
The USA's company animal population remains large and growing. The recent trend of humanizing our pets adds demand for preventive biologics such as vaccines and monoclonal antibodies. Similarly, the growing livestock sector is utilizing biologics to support the high quality and biosecurity of the food supply. R&D investments are significant, and collaborations between industry and academia often accelerate innovation. New Veterinary Biologics can experience delays from regulatory compliance, but there may be expedited approval pathways. The USA has been the leader in the inclusion of digital technologies to leverage and improve distribution and compliance, and has created a growth path. The U.S. market remains mature, and the growing consumer awareness and expanded product portfolio continue to provide growth opportunities for the foreseeable future.
Veterinary Biologics Market in Canada
Canada promotes a robust animal health ecosystem, particularly in poultry and cattle farming. It relies heavily on vaccination-based disease control through its Canadian Food Inspection Agency (CFIA), which also oversees approval and usage of biologics. Canada's emphasis on sustainable farming and reducing antibiotic use has sped up the adoption of biologics in both livestock and companion animals. Furthermore, government-supported research and development (R&D) grants and partnerships with biotechnology firms in the U.S. have improved the availability of biologics in rural and agricultural communities.
What Are the Key Drivers of Veterinary Biologics Market Growth in Europe?
With the United Kingdom, Germany and France leading due to high livestock numbers and authorities outlining health policy plans that include them, Europe is a mature market. The European Medicines Agency (EMA) is facilitating harmonisation across Europe to enhance collaboration and approval mechanisms in Europe. In Germany, sustainability and disease prevention in livestock farming are the two main drivers of biologics acceptance, while France is more focused on animal care in the pet market and in urban areas. The market is also seeing a gradual increase in demand for antibiotic-free animal health care solutions, which supports the move to biologics and disease management.
Veterinary Biologics Market in the United Kingdom
Veterinary biologics in the United Kingdom are set to grow at a compound annual growth rate (CAGR) of 5.5%, with a strong potential for growth throughout the forecast period. The UK is situated in a mature veterinary healthcare environment, with access to veterinary services at all levels. The companion animal market is driven by pet humanization, further facilitating the uptake of biologics. The regulatory landscape is overseen by the Veterinary Medicines Directorate (VMD), which is strict on safety standards but also very constructive in stimulating innovation through a simplified approval process. The growing need for sustainable livestock farming and zoonotic disease management continues to drive the market. In addition, public health campaigns for vaccination and animal welfare support demand in the market. Despite issues associated with regulatory changes stemming from Brexit, the UK has a well-developed supply chain and distribution chain that supports veterinary clinics and pharmacies. Research and partnerships provide governmental support to promote innovation in biologics. Investment in digital health is rising, leading to improved product traceability and compliance.
Veterinary Biologics Market in Germany
The market for veterinary biologics in Germany is set for strong growth with a substantial CAGR of 6.5% by 2032. The growth will be supported by Germany’s strong animal husbandry, which utilizes valuable, advanced biologics supporting sustainable farming and livestock production. Within veterinary healthcare, Germany benefits from a well-resourced infrastructure for veterinary healthcare to service a significant companion animal population increasingly likely to be serviced by preventive biologics, including vaccines and immunomodulatory products. Regulations in Germany are strong, with the Federal Institute for Veterinary Medicine (BVL) responsible for product strategies and regulations, and the BVL’s oversight reassures veterinarians by demonstrating both safety and efficacy, which unlocks greater opportunities for uptake of new biologics, both recombinant vaccines and monoclonal antibodies. The overall commitment to research and development is strong, with continued collaborations between biotech companies, academia, and public institutions, which facilitates the process of innovation. With the advent of integrating digital health into veterinary practices to ensure proper distribution of biologics, compliance and tracking, operational moments are made more efficient. Germany’s regulatory processes are lengthy and cumbersome, but lead to a premium, quality-driven marketplace in the EU. High demands exist for veterinary biologics to assist in controlling zoonotic diseases, addressing animal welfare, and the need for biosecurity. Germany is a highly desirable and strategically advantageous market in Europe with durable long-term growth prospects.
Veterinary Biologics Market in France
Veterinary biologics revenue in France is projected to grow at a CAGR of 6.2% by 2032. France supports a strong agricultural sector with a high density of livestock, which in turn drives demand for biologics, in particular vaccines, particularly for the bovine, porcine, and poultry segments. A relatively strong regulatory framework that sets many of the standards by ANSES (French Agency for Food, Environmental and Occupational Health & Safety) promotes confidence in the market, emphasizing safety and quality. The livestock producers' health programs of the government and biosecurity programs are also influencing increased adoption. Companion animal care is also increasing, along with pet ownership and pet owner spending on veterinary care. Local manufacturers and global manufacturers are investing in research & development of more robust vaccines and immunotherapy. The country has largely adapted to the EU equivalency since Brexit, and continues to provide for robust harmonized expectations to enable cross-border business. Increasing public knowledge surrounding zoonotic diseases and food safety is also influencing increased biologics adoption. Complexity in the regulatory framework and research and development expense are challenges; however, France continues to remain an attractive market with a balanced demand for biologics across livestock and companion animal segments.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Veterinary Biologics Market Drivers
Heightened Global Emphasis on Zoonotic Disease Prevention
Technological Advancement in Biologic Manufacturing
Veterinary Biologics Market Restraints
High costs of production and storage
Regulatory complexity and slow approval timelines
Request Free Customization of this report to help us to meet your business objectives.
The veterinary biologics industry includes several global pharmaceutical conglomerates, innovative biotech businesses, and select regional businesses that compete on product differentiation, geography, and approvals from regulatory agencies. Market-leading companies like Zoetis, Elanco Animal Health, Boehringer Ingelheim, Merck Animal Health, and Ceva Santé Animale have extensive product lines that include vaccines, immunomodulators, and recombinant biologics. The market leaders in veterinary biologics dedicate considerable resources to R&D and collaborate with universities, startup partners, and government research organizations to develop and commercialize biologics. Companies also create mergers, acquisitions, and alliances to offer products in developing markets and enhance their distribution capabilities. Meanwhile, regional manufacturers from Asia-Pacific and Latin America are uniquely positioned to offer cost-effective, locally relevant biologics products, focused on the livestock sector. As precision medicine and sustainable animal care continue to emerge in the marketplace, competitive intensity is likely to increase against a technological backdrop, differentiating innovatively and gaining regulatory approval.
Top Player’s in Veterinary Biologics Market
Recent Developments in Veterinary Biologics Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that collects, Collates, Correlates, and analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the veterinary biologics market, growth is driven by increasing emphasis on zoonotic disease prevention studies, advancement in biologic manufacturing techniques, and increasing government vaccination campaigns. The market is dominated by vaccines and at the same time new recombinant technologies are emerging as the fastest growing segment. By region, North America is the largest market with established and well-funded infrastructure, while Asia-Pacific, especially India and China, is experiencing the most rapid growth rate as an increased demand for livestock vaccination and pet care becomes increasingly prevalent. The space is also being disrupted by startups, like VetraGene Biologics (UK) and AniNova BioTech (India) with genome editing capabilities and thermostable formulations. Recent developments include AI vaccine platforms, recombinant manufacturing expansions, and blockchain-based cold chain tracking. Important drivers like a fundamental shift to next-generation biologics and the adoption and integration of digital technologies are reshaping competition and making veterinary biologics more efficient and scalable and offering a wider accessibility in diverse geographies.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 27.58 Billion |
| Market size value in 2033 | USD 40.32 Billion |
| Growth Rate | 4.31% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Veterinary Biologics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Veterinary Biologics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Veterinary Biologics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Veterinary Biologics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
